June 1, 2015
Bristol-Myers Booth in ASCO Annual Meeting in Chicago The PD-1 immune checkpoint inhibitor Opdivo (nivolumab) demonstrated an overall survival (OS) rate of 62% at 12 months in a PI/II trial conducted in patients with hepatocellular carcinoma (HCC) or advanced liver...read more